Pregled bibliografske jedinice broj: 938735
Novel Imidazole Aldoximes with Broad-Spectrum Antimicrobial Potency against Multidrug Resistant Gram-Negative Bacteria
Novel Imidazole Aldoximes with Broad-Spectrum Antimicrobial Potency against Multidrug Resistant Gram-Negative Bacteria // Molecules, 23 (2018), 5; 1212, 13 doi:10.3390/molecules23051212 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 938735 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Novel Imidazole Aldoximes with Broad-Spectrum
Antimicrobial Potency against Multidrug Resistant
Gram-Negative Bacteria
Autori
Skočibušić, Mirjana ; Odžak, Renata ; Ramić, Alma ; Smolić, Tomislav ; Hrenar, Tomica ; Primožič, Ines
Izvornik
Molecules (1420-3049) 23
(2018), 5;
1212, 13
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
imidazole 2-aldoximes ; quaternary imidazolium salts ; antimicrobial activity ; extended-spectrum β-lactamase (ESBL) ; multivariate analysis ; multidrug resistance
Sažetak
In the search for a new class of potential antimicrobial agents, five novel N-substituted imidazole 2-aldoximes and their six quaternary salts were evaluated. The antimicrobial activity was assessed against a panel of representative Gram-positive and Gram-negative bacteria, including multidrug resistant bacteria. All compounds demonstrated potent in vitro activity against the tested microorganisms, with MIC values ranging from 6.25 to 50.0 μg/mL. Among the tested compounds, two quaternary compounds (N-but-3-enyl- and meta- (10) or para- N-chlorobenzyl (11) imidazolium 2-aldoximes) displayed the most potent and broad-spectrum activity against both Gram- positive and Gram-negative bacterial strains. The broth microdilution assay was also used to investigate the antiresistance efficacy of the both most active compounds against a set of Enterobacteriaceae isolates carried a multiple extended-spectrum β-lactamases (ESBLs) in comparison to eight clinically relevant antibiotics. N-but-3-enyl-N-meta-chlorobenzyl imidazolium 2-aldoxime was found to possess promising antiresistance efficacy against a wide range of β-lactamases producing strains (MIC 2.0 to 16.0 μg/mL). Best results for that compound were obtained against Escherichia coli and Enterobacter cloacae producing multiple β- lactamases form A and C molecular classes, which were 32- and 128-fold more potent than ceftazidime and cefotaxime, respectively. To visualize the results, principal component analysis was used as an additional classification tool. The mixture of ceftazidime and compound 10 (3 μg:2 μg) showed a strong activity and lower the necessary amount (up to 40-fold) of 10 against five of ESBL-producing isolates (MIC ≤ 1 µg/mL).
Izvorni jezik
Engleski
Znanstvena područja
Kemija, Biologija, Interdisciplinarne prirodne znanosti
POVEZANOST RADA
Projekti:
HRZZ-IP-2016-06-3775 - Aktivnošću i in silico usmjeren dizajn malih bioaktivnih molekula (ADESIRE) (Hrenar, Tomica, HRZZ - 2016-06) ( CroRIS)
Ustanove:
Prirodoslovno-matematički fakultet, Zagreb,
Prirodoslovno-matematički fakultet, Split
Profili:
Tomislav Smolić
(autor)
Ines Primožič
(autor)
Alma Ramic
(autor)
Tomica Hrenar
(autor)
Mirjana Skočibušić
(autor)
Renata Odžak
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE